Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013)

The primary objective of this trial was to assess the feasibility, toxicity profile, and antitumor activity of gemtuzumab ozogamicin (GO) combined with a chemotherapy remission-induction regimen in adults with untreated high-risk myelodysplastic syndrome (HR-MDS) or secondary acute myeloid leukemia...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Hematol
Main Authors: de Witte, Theo, Suciu, Stefan, Meert, Liv, Halkes, Constantijn, Selleslag, Dominik, Bron, Dominique, Amadori, Sergio, Willemze, Roel, Muus, Petra, Baron, Frédéric
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2015
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4604495/
https://ncbi.nlm.nih.gov/pubmed/26410352
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-015-2486-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados